Payer Denial of Routine Care Costs Highlight Week in Health Care News

Article

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

[<a href="//storify.com/pharmacytimes/payer-denial-of-routine-care-costs-highlight" target="_blank">View the story "Payer Denial of Routine Care Costs Highlight Week in Health Care News" on Storify</a>]

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Related Content
Research Finds In Utero Exposure to Ocrelizumab Not Associated With Increased Adverse Pregnancy, Infant Outcomes for Women With MS

Research Finds In Utero Exposure to Ocrelizumab Not Associated With Increased Adverse Pregnancy, Infant Outcomes for Women With MS

Aislinn Antrim, Assistant Managing Editor
June 1st 2024
Article
Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

January 25th 2024
Podcast
Subcutaneous Ocrelizumab Provides New Administration Opportunities for Multiple Sclerosis

Subcutaneous Ocrelizumab Provides New Administration Opportunities for Multiple Sclerosis

Aislinn Antrim, Assistant Managing Editor
May 31st 2024
Article
Pharmacy Focus: Policy Edition - PBM Audits

Pharmacy Focus: Policy Edition - PBM Audits

January 24th 2024
Podcast
Pharmacists Compare Experiences With Multiple Sclerosis at Large Academic Institutions, Small Private Practices

Pharmacists Compare Experiences With Multiple Sclerosis at Large Academic Institutions, Small Private Practices

Aislinn Antrim, Assistant Managing Editor
May 30th 2024
Article
Carefully Consider Strategies When Switching Disease-Modifying Therapies for MS

Carefully Consider Strategies When Switching Disease-Modifying Therapies for MS

Aislinn Antrim, Assistant Managing Editor
May 30th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.